Irbesartan And Hydrochlorothiazide Milpharm (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing the hormone from causing vasoconstriction and stimulating aldosterone release. This results in relaxed blood vessels and reduced fluid retention, contributing to lower systemic blood pressure.

Hydrochlorothiazide acts on the distal convoluted tubule of the kidney, inhibiting sodium‑chloride reabsorption. The increased excretion of sodium and water reduces blood volume, which together with Irbesartan’s vasodilatory effect helps achieve better blood‑pressure control.

The prescribed dose is individualized by the treating physician based on the patient’s current blood‑pressure readings, renal function, electrolyte status and overall clinical response. No fixed dosing regimen is provided here; the prescriber decides the appropriate strength and frequency.

Safety data for this combination in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy, the Irbesartan/HCTZ combination offers additive blood‑pressure reduction by targeting both the renin‑angiotensin system and renal sodium handling. It can be an alternative to an ACE‑inhibitor plus thiazide or to higher‑dose single agents, often providing better control with a single tablet.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Patients should swallow the tablet whole and follow any specific instructions regarding timing relative to other medicines.

Serious adverse events include severe hypotension, acute kidney injury, hyperkalemia, and allergic reactions such as rash or angioedema. Patients should be monitored for signs of these conditions, especially during treatment initiation or dose changes.

The combination should be avoided in individuals with known hypersensitivity to either component, severe renal impairment, uncontrolled hyperkalemia, or in patients who are severely dehydrated. Clinicians should also exercise caution in patients with hepatic dysfunction.